Technical Analysis for GLS - Gelesis Holdings, Inc.

Grade Last Price % Change Price Change
F 4.7 -15.16% -0.84
GLS closed down 15.16 percent on Thursday, January 20, 2022, on 81 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical GLS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -15.16%
Older End-of-Day Signals for GLS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% about 12 hours ago
Down 1 ATR about 12 hours ago
Down 5% about 13 hours ago
Fell Below Previous Day's Low about 14 hours ago
New 52 Week Low about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Gelesis Holdings, Inc. Description

Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Our non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Our portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.


Sector: Financial Services
Industry: Shell Companies
Keywords: Medicine Clinical Medicine Diabetes FDA Steatohepatitis Hepatitis Non Alcoholic Fatty Liver Disease Weight Management Fatty Liver Disease Functional Constipation Hydrogel

Is GLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.23
52 Week Low 4.56
Average Volume 273,015
200-Day Moving Average 9.76
50-Day Moving Average 9.42
20-Day Moving Average 8.64
10-Day Moving Average 7.31
Average True Range 0.82
ADX 38.59
+DI 20.31
-DI 35.32
Chandelier Exit (Long, 3 ATRs) 9.78
Chandelier Exit (Short, 3 ATRs) 7.01
Upper Bollinger Bands 12.33
Lower Bollinger Band 4.94
Percent B (%b) -0.03
BandWidth 85.58
MACD Line -1.15
MACD Signal Line -0.66
MACD Histogram -0.4923
Fundamentals Value
Market Cap 129.72 Million
Num Shares 27.6 Million
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.71
Resistance 3 (R3) 6.89 6.39 6.38
Resistance 2 (R2) 6.39 5.88 6.31 6.26
Resistance 1 (R1) 5.55 5.57 5.30 5.37 6.15
Pivot Point 5.05 5.05 4.93 4.97 5.05
Support 1 (S1) 4.21 4.54 3.96 4.03 3.25
Support 2 (S2) 3.71 4.23 3.63 3.14
Support 3 (S3) 2.87 3.71 3.03
Support 4 (S4) 2.69